ストックスクリーナーアプリを入手
18.48
3.65%
0.65
Arvinas Inc (ARVN) 最新ニュース
Arvinas (NASDAQ:ARVN) Trading Down 6.2%Time to Sell? - MarketBeat
Arvinas (NASDAQ:ARVN) Sets New 12-Month LowWhat's Next? - MarketBeat
New Haven-based Arvinas to expand Science Park footprint; renews leases - Hartford Business Journal
New Haven-based Arvinas to expand Science Park footprint; extends leases - Hartford Business Journal
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results By Investing.com - Investing.com Australia
Arvinas's SWOT analysis: biotech firm's stock faces pivotal trial results - Investing.com
Metastatic Prostate Cancer Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Merck Sharp, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart
Arvinas secures expanded New Haven premises until 2029 By Investing.com - Investing.com South Africa
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Increases By 5.6% - MarketBeat
Arvinas stock touches 52-week low at $21.17 amid market challenges - Investing.com Canada
(ARVN) Trading Advice - Stock Traders Daily
Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Lowers Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas's SWOT analysis: protein degrader's stock faces pivotal trial - Investing.com India
Arvinas, Pfizer’s vepdegestrant shows promise in ER+/HER2- breast cancer trial - World Pharmaceutical Frontiers
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - MarketBeat
Demystifying Arvinas: Insights From 5 Analyst Reviews - Benzinga
Arvinas and Pfizer’s combo therapy shows promise in breast cancer trial - Yahoo! Voices
Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients - Yahoo Finance
Arvinas and Pfizer Report Promising Cancer Study Results - TipRanks
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium - The Manila Times
Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium - XM
Arvinas and Pfizer Announce Initial Phase 1b Data from the - GlobeNewswire
Arvinas & Pfizer's Breast Cancer Drug Shows Promising 62.5% Clinical Benefit Rate in Phase 1b Trial - StockTitan
BTIG Research Initiates Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Verition Fund Management LLC Sells 52,720 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Fmr LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Shares Sold by RTW Investments LP - MarketBeat
Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Parkman Healthcare Partners LLC Sells 28,978 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
405,576 Shares in Arvinas, Inc. (NASDAQ:ARVN) Purchased by Baker BROS. Advisors LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ARVN) Investment Report - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect - AccessWire
Wasatch Advisors LP Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Braidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - AccessWire
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN) - Simply Wall St
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation - AccessWire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Lessened by Victory Capital Management Inc. - Defense World
Arvinas to Present at Piper Sandler Healthcare Conference; Leadership to Share Updates | ARVN Stock News - StockTitan
BMO keeps Outperform rating on Arvinas shares, excited about vepdegestrant's progress - Investing.com
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):